Breaking News
FONT-SIZE Plus   Neg
Share SHARE

GSK Report Data From PhaseIII Study Of Once-weekly Albiglutide In Type2 Diabetes

GlaxoSmithKline Plc (GSK: Quote, GSK.L) announced new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes. The company said that detailed findings from a Phase III study comparing the investigational glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide to prandial insulin (Lispro), were presented at the American Diabetes Association Meeting or ADA in Philadelphia, USA, and show that the effect is maintained out to 52 weeks.

In Harmony 6, a 52-week randomised open label multicentre study among patients with Type 2 diabetes who were inadequately controlled on intermediate or long-acting insulin, albiglutide (30mg with optional titration to 50mg) was compared to Lispro, each administered in combination with long-acting insulin glargine. As previously disclosed, at 26 weeks, albiglutide showed clinically and statistically significant reductions.

The company noted that data also show that weight changes from baseline observed at 26 weeks for patients in the albiglutide arm (-0.73kg loss) vs the Lispro arm (+0.81kg gain) were sustained at 52 weeks (-0.96kg vs +1.66kg; p<0.0001 for treatment difference).

The company stated that Fasting plasma glucose (FPG) decreased from baseline in both study arms throughout the 52 week period (-27mg/dL in the albiglutide arm compared to -16mg/dL in the Lispro arm; p=0.0281 for treatment difference.

Results of Harmony 7, a 32-week head-to-head study comparing albiglutide (50mg) to once-daily liraglutide (1.8mg), were also presented as a poster at the ADA. As previously disclosed, albiglutide demonstrated a statistically significant reduction in HbA1c from baseline (-0.78%; p<0.0001) but did not meet the pre-specified primary endpoint of non-inferiority to liraglutide (-0.99%; 95% CI: 0.08-0.34%; p=NS).

The proportion of patients achieving a clinically meaningful HbA1c target level of <7.0 at week 32 was higher in the liraglutide arm (52%) compared to the albiglutide arm (42%; p=0.0023 for treatment difference).

Albiglutide is an investigational biological, injectable form of human GLP-1. It is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world.

GSK is developing albiglutide as a once-weekly injection using a fine gauge needle for reconstitution and subcutaneous administration by the patient.

In a separate press release, Human Genome Sciences said that it is entitled to fees and milestone payments that could amount to as much as $183 million - including $33.0 million received to date - in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.

Register
To receive FREE breaking news email alerts for GlaxoSmithKline PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Reserve Bank of Australia Governor Glenn Stevens kept the foreign exchange intervention plan open to build up confidence and bring the stubbornly high currency to lower levels."The exchange rate, another channel through which monetary policy usually has an effect, is probably not doing as much as it might usually be expected to do in achieving balanced growth," he said in his opening statement. Stocks turned in another strong performance during trading on Tuesday, extending the upward trend seen over the past several sessions. The gains on the day once again lifted the tech-heavy Nasdaq to a new fourteen-year closing high. President Barack Obama revealed Monday that he is dispatching Attorney General Eric Holder to Ferguson, Missouri, amid ongoing violence in the St. Louis suburb. Obama said Holder will travel to Ferguson on Wednesday to meet with the FBI agents and Justice Department personnel conducting an investigation of the shooting death of Michael Brown.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.